3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Colorectal Neoplasms
43
Rectal Neoplasms
12
Colonic Neoplasms
12
Neoplasm Metastasis
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Gallbladder Neoplasms
3
Colorectal Cancer Metastatic
3
Cholangiocarcinoma
3
Neutropenia
2
Neoplasms
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
mCRC
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Recurrence
1
Pretreated Metastatic Colorectal Cancer
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Carcinoma
1
Microsatellite-stable Colorectal Cancer
1
Metastatic Gastric Adenocarcinoma
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric and Gastroesophageal Junction Adenocarcinoma
1
Gastric Cancer Adenocarcinoma Metastatic
1
Gastric Adenocarcinoma
1
Interventions
Cisplatin
21
pembrolizumab
16
Gemcitabine
16
Paclitaxel
15
Radiotherapy
14
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
9
Cetuximab
9
Magnetic Resonance Spectroscopy
8
Radiation
7
padeliporfin
6
Specimen Handling
6
Oxaliplatin
6
Fluorouracil
6
Drug Therapy
6
Docetaxel
6
Capecitabine
6
Bevacizumab
6
anlotinib
5
Nivolumab
5
Irinotecan
5
Erlotinib Hydrochloride
5
Celecoxib
5
poly ICLC
4
fludarabine
4
Standard of Care
4
Sorafenib
4
Leucovorin
4
Ipilimumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma
×
trifluridine tipiracil drug combination
×
Clear all
NCT02920476
2022-06-23
UF-STO-LUNG-003
University of Florida
Phase 2
Completed
4 enrolled
8 charts